Archived explainer. For the current picture see today's COGT page.
COGENT BIOSCIENCES I (COGT) is down -6.81% in the latest session. Our newswire has captured 2 stories on COGT across 2 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
Cogent Biosciences (COGT) shares fell 6.81% to $38.70 in the session as the company announced a $400 million at-the-market offering. The move reflects investor concern over the dilutive impact of the offering, which may pressure the stock further in the near term.
On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Exchange Commission, disclosing its intent to offer up to $400 million in common stock through an at-the-market offering. This filing was accompanied by an 8-K filing that outlined the details under Items 8.01 and 9.01. The announcement came amid a backdrop of recent positive developments, including a Q2 earnings beat and a new drug application filing for bezuclastinib in advanced systemic mastocytosis. However, the market reacted negatively to the news of the large-scale stock offering, which is seen as a potential dilutive move for existing shareholders.
The stock has traded between $10.70 and $43.73 over the past 52 weeks, with a current market capitalization of $7.1 billion. Despite a recent earnings beat and ongoing clinical progress, the company remains unprofitable, with a trailing twelve-month EPS of -2.51. The stock has a beta of 0.33, indicating lower volatility than the broader market. The 30-day average sentiment score was 52 out of 100, but it has declined to 48 in the past week, reflecting deteriorating investor sentiment. The session’s sharp decline has pushed the stock closer to its 52-week low, with volume likely above its average as the market digests the offering news.
Investors should monitor the full execution of the $400 million offering and its impact on share price and ownership structure. The company is also scheduled to present preclinical data at the 2026 European Hematology Association Congress in June, which may influence investor sentiment in the coming months.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
An update from Cogent Biosciences ( ($COGT) ) is now available. On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Ex...
Filed: 2026-08-10 AccNo: 0001193125-26-342695 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
More on COGT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier COGT move explainers: 2026-08-12 · 2026-08-11